Vertex Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst on November 5. Analyst David Dai from UBS maintained a Buy rating on the stock and has a $553.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
David Dai has given his Buy rating due to a combination of factors, including Vertex Pharmaceuticals’ strong revenue performance and promising future prospects. The company reported a revenue beat for the third quarter of 2025, with $3.08 billion in revenue, exceeding both UBS estimates and consensus expectations. This was largely driven by higher-than-expected sales of Trikafta/Kaftrio, which reached $2.65 billion.
Despite some setbacks with Alyftrek and Journavx, where sales fell short of expectations, the overall outlook remains positive. The management’s confidence in improving gross-to-net figures and the potential for increased patient comfort with liver monitoring could enhance Alyftrek’s performance. Additionally, the upcoming interim readout of the povetacicept Phase 3 trial in IgAN could provide significant upside potential for the stock, especially if the data is favorable compared to competitors. These factors collectively support the Buy rating for Vertex Pharmaceuticals.
Dai covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Telix Pharmaceuticals, and IDEAYA Biosciences. According to TipRanks, Dai has an average return of -5.6% and a 44.44% success rate on recommended stocks.
In another report released on November 5, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $486.00 price target.